Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
about
Pentasaccharides for the treatment of deep vein thrombosisAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerUnfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patientsOnce versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolismAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismOnce versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolismAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesDeep Venous Thrombosis: An Interventionalist's ApproachIncidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.Safety of low molecular weight heparins in the treatment of venous thromboembolism.Heparin-induced thrombocytopenia from venous thromboembolism treatment.Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis.Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.Once versus twice daily LMWH for the initial treatment of venous thromboembolism.Reviparin as prophylaxis for thromboembolism after leg injury and hip replacement.Catheter-directed thrombolysis for deep venous thrombosis.Evaluation of the Oral Bioavailability of Low Molecular Weight Heparin Formulated With Glycyrrhetinic Acid as Permeation EnhancerManagement of thrombosis in cancer: primary prevention and secondary prophylaxis.Update on the diagnosis and management of pulmonary embolism.Cost analysis before and after implementation of a computerized physician order entry order form for enoxaparin.Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials.Therapeutic monitoring of unfractionated heparin - trials and tribulations.Iatrogenic IVC Perforation after Successful Catheter-Directed Thrombolysis.Optimization of experimental parameters for the production of LMWH-loaded polymeric microspheres.Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions.Diagnosis and anticoagulant treatment.Pentasaccharides for the treatment of deep vein thrombosis.Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.Development and characterization of polymer lipid hybrid nanoparticles for oral delivery of LMWH.Approach to venous thromboembolism in the cancer patient.
P2860
Q24186811-CBEA5243-852A-4081-9165-854B7B17E354Q24193871-52390567-55D1-4106-B8E5-134191AFDAF6Q24200589-2E06EA3E-047D-467D-A370-B1B06AFA82EFQ24201186-28D17477-4C06-4119-97AD-49AF58A4CE4AQ24234155-0B3D33FF-D600-4137-8AD9-E903EEEECA07Q24235193-5BB4C857-72D0-49FB-B870-B7DBA53249ADQ24235236-AC177001-A100-42E1-A5B3-7CF7C2FC9E97Q24236443-17D412C0-6F2E-47AF-82BF-FC4853867B21Q24242243-20EAD99B-D41F-4E7B-A4F5-D469EA57DAD6Q24245782-A762578A-5B68-49F3-87D1-633EBE8D0C56Q24246284-D5064191-EB05-4012-94CB-C0EA11A05A37Q24633053-201CB84A-BAB8-4ED7-8522-EA29C13F51B2Q26827598-31C7E29F-1530-4C33-BEC7-6724BCF2B7FBQ33343961-9E8E2738-EA6E-4F3D-8B79-F5949B78C69CQ33349368-938D6F95-EEF4-4813-AF11-ABD2F3BBD179Q33369355-6E36594D-3C29-4777-8D70-F7EB0AEF9EA5Q33416866-613D1DD4-FE96-4326-AE2A-0F1AA705A56CQ33441234-B1E25A6A-E84C-4FFA-A500-8A339674D2F7Q33967251-8A782F1D-2C46-4FED-9440-2DCC023FEB30Q34415964-EE4A7859-BF04-41EF-96BD-2280F122BB24Q34550908-D1DF82A0-BC70-4E6F-870A-63FE686F60FEQ35048657-5D22CA2D-E203-488C-870A-482AEE925181Q35058141-E70B5A5B-7642-48ED-A962-086E99733C44Q35647925-448CF5B6-D59C-4366-8CD2-72A16C98F9DDQ35941004-092F961E-1716-4CE5-8C96-0369B0F0F030Q36018537-50599AD9-DEED-42EA-963C-5C761316EEAAQ36286443-9BD76D7D-FEC4-4934-9D89-094F5600E132Q38011153-7804CB16-BFF4-407C-A763-26FB13FC547DQ38395008-C4CF3117-FA94-42CB-A641-120AE6E4F42BQ38669011-00458B11-D62D-40BD-9ADF-66779FDECA8FQ41688178-2881DE22-9A31-4142-A178-962F6161EBB2Q42089227-BBE254B9-A243-498A-82A7-6DCA757FB908Q42352700-7A3DD078-76A9-409D-885B-14D946E11025Q45847579-CAE09742-F2E8-4939-A2A1-7263840BF21EQ47376811-118A8AC5-4EC8-49C8-92EE-AAC767C9C09AQ48162860-2600F8AF-CD6D-44D3-9C04-0F12A37A8F22Q48874719-2BD560E9-7900-40D9-93C9-56ED950E50FAQ53160538-0DCD5545-67E6-47D0-B89F-47E135FA893A
P2860
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@ast
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@en
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@nl
type
label
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@ast
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@en
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@nl
prefLabel
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@ast
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@en
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@nl
P2093
P921
P1476
Effects of a low-molecular-wei ...... nts with deep-vein thrombosis.
@en
P2093
CORTES Investigators. Clivarin ...... rombosis, Efficacy, and Safety
H K Breddin
V Hach-Wunderle
V V Kakkar
P304
P356
10.1056/NEJM200103013440902
P407
P577
2001-03-01T00:00:00Z